Adherium Adds AUD 1 Million Unsecured Loan Facility at 12% Interest
Adherium has tapped its major shareholder, Trudell Medical, for a further AUD 1 million unsecured loan to bolster working capital, adding to a recent USD 1.65 million facility.
- AUD 1 million unsecured loan facility from Trudell
- 12% annual interest with monthly capitalisation
- Repayment due 30 September 2026 with possible extensions
- Loan avoids shareholder dilution amid limited funding options
- Board deems terms arm's length without need for shareholder approval
Additional Funding from Major Shareholder
Adherium Limited (ASX:ADR) has arranged an extra AUD 1 million short-term unsecured loan from its largest shareholder, Trudell Medical Limited. This new facility supplements a USD 1.65 million loan from Trudell announced less than two months ago, underscoring the company's ongoing need for working capital support.
Loan Terms and Repayment Flexibility
The loan carries an interest rate of 12% per annum, with interest capitalised monthly until repayment. Adherium can draw down funds as required and may repay the loan at any time without penalty. The repayment is scheduled for 30 September 2026 but can be extended month to month by mutual agreement. The facility is unsecured, exposing Trudell to credit risk but offering Adherium flexibility in managing its cash flow.
Board’s Rationale for Related-Party Funding
Adherium’s board, excluding Mr George Baran who is affiliated with Trudell, concluded that obtaining funding from Trudell was preferable given limited alternative financing options. The company highlighted that the loan avoids shareholder dilution, offers reasonable interest terms, and can be executed quickly compared to third-party funding. This arrangement is considered arm’s length and does not require shareholder approval under the Corporations Act.
Context Within Adherium’s Capital Strategy
This latest loan facility arrives as Adherium continues to navigate its capital structure following recent shareholder approvals for a 1-for-100 share consolidation and capital raises earlier in 2026. The company has been actively managing liquidity while pursuing growth in its digital respiratory management business, which recently reported record remote patient monitoring revenue and strong clinical validation for its Hailie Smartinhaler platform.
Bottom Line?
Adherium’s reliance on repeated related-party loans highlights ongoing working capital pressures amid limited external funding options.
Questions in the middle?
- Will Adherium secure more sustainable financing beyond short-term loans?
- How will repeated loan extensions affect the company’s credit profile?
- What impact might these funding arrangements have on future shareholder value?
